Recent Business Highlights
Future
Current
Multidimensional business model to sustain long-term
growth
•
UNBRANDED
(US + EU)
Monetize the complex/limited
competition assets across
channels and classes of trade
BRANDED
(EM + INDIA)
Continued growth for mega
brands through patient centric
initiatives
Selective business integration
on NCE assets
PROPRIETARY
PRODUCTS
Maximize the base business
revenues through volume
growth initiatives and
managed care strategy
Accelerate Biosimilars filings
in US and EU
Outreach model for novel
dosage forms in Non-
traditional channels
Accelerate the journey to
monetize Biosimilars assets
across existing and new
markets
Focus on development and
filing of late-stage, high-value
differentiated assets
PSAI
Leverage Industry leading chemistry skills to synthesize complex
APIs enabling robust portfolio across the businesses
7View entire presentation